Dec 6 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and ...

Investing.com - Morgan Stanley upgraded Vertex Pharmaceuticals (NASDAQ:VRTX) from Equalweight to Overweight on Wednesday, raising its price target to $516.00 from $438.00. The new target represents ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in wondering what the right move is. The stock's recent momentum may have caught ...

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including federal ...